{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,4,27]],"date-time":"2024-04-27T18:35:23Z","timestamp":1714242923912},"reference-count":24,"publisher":"MJS Publishing, Medical Journals Sweden AB","license":[{"start":{"date-parts":[[2024,4,2]],"date-time":"2024-04-02T00:00:00Z","timestamp":1712016000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Derm Venereol"],"abstract":"<jats:p>Abstract is missing (Short communication)<\/jats:p>","DOI":"10.2340\/actadv.v104.19672","type":"journal-article","created":{"date-parts":[[2024,4,3]],"date-time":"2024-04-03T06:53:48Z","timestamp":1712127228000},"page":"adv19672","source":"Crossref","is-referenced-by-count":1,"title":["Adrenal Insufficiency after Long-term use of Topical Glucocorticoids in Patients with Advanced Cutaneous T-cell Lymphomas: A Case Series"],"prefix":"10.2340","volume":"104","author":[{"given":"Valerie","family":"Glutsch","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Schummer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann-Cathrin","family":"Koschker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Goebeler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marion","family":"Wobser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1183","published-online":{"date-parts":[[2024,4,2]]},"reference":[{"key":"54892","doi-asserted-by":"crossref","unstructured":"Dippel E, Assaf C, Becker JC, von Bergwelt-Baildon M, Bernreiter S, Cozzio A, et al. S2k-Guidelines - Cutaneous lymphomas (ICD10 C82 - C86): Update 2021. J Dtsch Dermatol Ges 2022; 20: 537-554.","DOI":"10.1111\/ddg.14706"},{"key":"54893","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/ddg.14706","DOI":"10.1111\/ddg.14706"},{"key":"54894","doi-asserted-by":"crossref","unstructured":"Hengge UR, Ruzicka T, Schwartz RA, Cork MJ. Adverse effects of topical glucocorticosteroids. J Am Acad Dermatol 2006; 54: 1-15; quiz 16-18.","DOI":"10.1016\/j.jaad.2005.01.010"},{"key":"54895","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaad.2005.01.010","DOI":"10.1016\/j.jaad.2005.01.010"},{"key":"54896","doi-asserted-by":"crossref","unstructured":"Phan K, Smith SD. Topical corticosteroids and risk of diabetes mellitus: systematic review and meta-analysis. J Dermatolog Treat 2021; 32: 345-349.","DOI":"10.1080\/09546634.2019.1657224"},{"key":"54897","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1080\/09546634.2019.1657224","DOI":"10.1080\/09546634.2019.1657224"},{"key":"54898","doi-asserted-by":"crossref","unstructured":"Tempark T, Phatarakijnirund V, Chatproedprai S, Watcharasindhu S, Supornsilchai V, Wananukul S. Exogenous Cushing's syndrome due to topical corticosteroid application: case report and review literature. Endocrine 2010; 38: 328-334.","DOI":"10.1007\/s12020-010-9393-6"},{"key":"54899","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s12020-010-9393-6","DOI":"10.1007\/s12020-010-9393-6"},{"key":"54900","doi-asserted-by":"crossref","unstructured":"Nguyen CV, Bohjanen KA. Skin-directed therapies in cutaneous T-cell lymphoma. Dermatol Clin 2015; 33: 683-696.","DOI":"10.1016\/j.det.2015.05.004"},{"key":"54901","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.det.2015.05.004","DOI":"10.1016\/j.det.2015.05.004"},{"key":"54902","doi-asserted-by":"crossref","unstructured":"Bockle BC, Jara D, Nindl W, Aberer W, Sepp NT. Adrenal insufficiency as a result of long-term misuse of topical corticosteroids. Dermatology 2014; 228: 289-293.","DOI":"10.1159\/000358427"},{"key":"54903","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1159\/000358427","DOI":"10.1159\/000358427"},{"key":"54904","doi-asserted-by":"crossref","unstructured":"Levin C, Maibach HI. Topical corticosteroid-induced adrenocortical insufficiency: clinical implications. Am J Clin Dermatol 2002; 3: 141-147.","DOI":"10.2165\/00128071-200203030-00001"},{"key":"54905","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2165\/00128071-200203030-00001","DOI":"10.2165\/00128071-200203030-00001"},{"key":"54906","doi-asserted-by":"crossref","unstructured":"Prince HM, Kim YH, Horwitz SM, Dummer R, Scarisbrick J, Quaglino P, et al. Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. Lancet 2017; 390: 555-566.","DOI":"10.1016\/S0140-6736(17)31266-7"},{"key":"54907","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/S0140-6736(17)31266-7","DOI":"10.1016\/S0140-6736(17)31266-7"},{"key":"54908","doi-asserted-by":"crossref","unstructured":"Kim YH, Bagot M, Pinter-Brown L, Rook AH, Porcu P, Horwitz SM, et al. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncol 2018; 19: 1192-1204.","DOI":"10.1016\/S1470-2045(18)30379-6"},{"key":"54909","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/S1470-2045(18)30379-6","DOI":"10.1016\/S1470-2045(18)30379-6"},{"key":"54910","doi-asserted-by":"crossref","unstructured":"Gonzalez-Rodriguez E, Rodriguez-Abreu D, Spanish Group for Cancer I-B. Immune checkpoint inhibitors: review and management of endocrine adverse events. Oncologist 2016; 21: 804-816.","DOI":"10.1634\/theoncologist.2015-0509"},{"key":"54911","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1634\/theoncologist.2015-0509","DOI":"10.1634\/theoncologist.2015-0509"},{"key":"54912","doi-asserted-by":"crossref","unstructured":"Willemze R, Cerroni L, Kempf W, Berti E, Facchetti F, Swerdlow SH, et al. The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. Blood 2019; 133: 1703-1714.","DOI":"10.1182\/blood-2018-11-881268"},{"key":"54913","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1182\/blood-2018-11-881268","DOI":"10.1182\/blood-2018-11-881268"},{"key":"54914","doi-asserted-by":"crossref","unstructured":"Olsen E, Vonderheid E, Pimpinelli N, Willemze R, Kim Y, Knobler R, et al. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 2007; 110: 1713-1722.","DOI":"10.1182\/blood-2007-03-055749"},{"key":"54915","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1182\/blood-2007-03-055749","DOI":"10.1182\/blood-2007-03-055749"}],"container-title":["Acta Dermato-Venereologica"],"original-title":[],"link":[{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/19672\/45672","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/19672\/45672","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,3]],"date-time":"2024-04-03T06:53:59Z","timestamp":1712127239000},"score":1,"resource":{"primary":{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/view\/19672"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,2]]},"references-count":24,"URL":"https:\/\/doi.org\/10.2340\/actadv.v104.19672","relation":{},"ISSN":["1651-2057","0001-5555"],"issn-type":[{"value":"1651-2057","type":"electronic"},{"value":"0001-5555","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4,2]]}}}